products  amgen about back about overview the amgen difference quick facts mission and values leadership how we operate back how we operate overviewcorporate governancebusiness ethics and compliancepolicies practices and disclosures awards and accolades back awards and accolades overview amgen history science back science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials back clinical trials overviewabout clinical trialsamgen clinical trialsinformation for healthcare professionalsclinical trial transparency data sharing and disclosure practicesclinical outofhours support programinvestigator sponsored studies manufacturing biosimilars products back products overview medical information global patient safety back global patient safety overviewadverse event and product complaint reporting counterfeit drug statement safety data sheets responsibility back responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation back amgen foundation overviewprograms for students programs for teachers about the amgen foundation staff engagement access to medicine back access to medicine overviewreimbursement support services and financial assistance programsaccess to investigational medicinesthe value of our medicines environment supplier sustainability grants and giving back grants and giving overviewamgen foundation grantsindependent medical education fundingus healthcare donationsnonhealthcare donations and sponsorshipsequipment donationsdonation and grant recipient list safety and wellness back safety and wellness overviewsafetywellness reporting and metrics contact us back contact us locations product inquiries investors media partners careers amgen worldwide back amgen worldwide australia  english austria  deutsch brazil  português bulgaria  български canada  english canada  français china  english china   croatia  hrvatski czech republic  český denmark  dansk finland  suomen kieli france  français germany  deutsch greece  ελληνικά hong kong   hong kong  english hungary  magyarország ireland  english italy  italiano japan  english japan   korea  english korea  한국어 mexico  español netherlands  english netherlands  nederlands norway  norsk poland  język polski portugal  português romania  limba română russia  русский язык singapore  english slovakia  slovenčina slovenia  slovenščina spain  español sweden  svenska switzerland  français switzerland  deutsch taiwan  english taiwan   thailand  english thailand  ไทย turkey  türkçe united kingdom  english united states  english web resources back web resources science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology search amgen worldwide web resources amgen worldwide a biotechnology pioneer since  amgen has reached millions of patients around the world australia english austria deutsch brazil português bulgaria български canada english  français china english   croatia hrvatski czech republic český denmark dansk finland suomen kieli france français germany deutsch greece ελληνικά hong kong   english hungary magyarország ireland english italy italiano japan english   korea english  한국어 mexico español netherlands english  nederlands norway norsk poland język polski portugal português romania limba română russia русский язык singapore english slovakia slovenčina slovenia slovenščina spain español sweden svenska switzerland français  deutsch taiwan english   thailand english  ไทย turkey türkçe united kingdom english united states english web resources amgen has developed a collection of online resources available to help you learn more about areas of interest science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology about overview the amgen difference quick facts mission and values leadership how we operate awards and accolades amgen history science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials manufacturing biosimilars products overview medical information global patient safety counterfeit drug statement safety data sheets responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation access to medicine environment supplier sustainability grants and giving safety and wellness reporting and metrics × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site products amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options with a presence in approximately  countries we are proud to have reached millions of people with our products the product information provided below is intended for residents of the us only for information in other countries please select your country from the amgen worldwide menu above × products overview medical information global patient safety counterfeit drug statement safety data sheets in this section medical information intended for us healthcare professionals this application provides information on submitting inquiries prescribing information and speaking directly to a medical information healthcare professional global patient safety amgen is committed to patient safety and the global patient safety department is responsible for oversight of pharmacovigilance activity patient safety is our highest priority to fulfill our commitment to patient safety amgen’s global patient safety team applies a comprehensive continuous and rigorous approach to pharmacovigilance counterfeit drug statement amgen takes the issue of counterfeit drugs very seriously and is committed to the highest standards of drug quality and patient safety safety data sheets safety data sheets provide information for healthcare professionals and others seeking information on implications of the exposure to our products in the workplace related links access to medicine pipeline clinical trials amgen inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › amgen inc print share amgen inc address amgen inc one amgen center drive thousand oaks ca contact detailsphone  website wwwamgencomcareers wwwamgencomcareerscareershtmlpatient assistance program wwwamgenassistcomsupportprograms drugs associated with amgen incamgen inc manufactures markets andor distributes more than  drugs in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating amjevita generic name adalimumab class antirheumatics tnf alfa inhibitors na aranesp generic name darbepoetin alfa class recombinant human erythropoietins      blincyto generic name blinatumomab class miscellaneous antineoplastics na corlanor generic name ivabradine class miscellaneous cardiovascular agents      enbrel generic name etanercept class antirheumatics tnf alfa inhibitors      epogen generic name epoetin alfa class recombinant human erythropoietins      imlygic generic name talimogene laherparepvec class miscellaneous antineoplastics na kyprolis generic name carfilzomib class proteasome inhibitors na neulasta generic name pegfilgrastim class colony stimulating factors      neupogen generic name filgrastim class colony stimulating factors      nexavar generic name sorafenib class multikinase inhibitors vegfvegfr inhibitors      nplate generic name romiplostim class plateletstimulating agents      parsabiv generic name etelcalcetide class calcimimetics na prolia generic name denosumab class miscellaneous bone resorption inhibitors      repatha generic name evolocumab class pcsk inhibitors      repatha pushtronex generic name evolocumab class pcsk inhibitors na sensipar generic name cinacalcet class calcimimetics      vectibix generic name panitumumab class egfr inhibitors      xgeva generic name denosumab class miscellaneous bone resorption inhibitors      latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen about back about overview the amgen difference quick facts mission and values leadership how we operate back how we operate overviewcorporate governancebusiness ethics and compliancepolicies practices and disclosures awards and accolades back awards and accolades overview amgen history science back science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials back clinical trials overviewabout clinical trialsamgen clinical trialsinformation for healthcare professionalsclinical trial transparency data sharing and disclosure practicesclinical outofhours support programinvestigator sponsored studies manufacturing biosimilars products back products overview medical information global patient safety back global patient safety overviewadverse event and product complaint reporting counterfeit drug statement safety data sheets responsibility back responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation back amgen foundation overviewprograms for students programs for teachers about the amgen foundation staff engagement access to medicine back access to medicine overviewreimbursement support services and financial assistance programsaccess to investigational medicinesthe value of our medicines environment supplier sustainability grants and giving back grants and giving overviewamgen foundation grantsindependent medical education fundingus healthcare donationsnonhealthcare donations and sponsorshipsequipment donationsdonation and grant recipient list safety and wellness back safety and wellness overviewsafetywellness reporting and metrics contact us back contact us locations product inquiries investors media partners careers amgen worldwide back amgen worldwide australia  english austria  deutsch brazil  português bulgaria  български canada  english canada  français china  english china   croatia  hrvatski czech republic  český denmark  dansk finland  suomen kieli france  français germany  deutsch greece  ελληνικά hong kong   hong kong  english hungary  magyarország ireland  english italy  italiano japan  english japan   korea  english korea  한국어 mexico  español netherlands  english netherlands  nederlands norway  norsk poland  język polski portugal  português romania  limba română russia  русский язык singapore  english slovakia  slovenčina slovenia  slovenščina spain  español sweden  svenska switzerland  français switzerland  deutsch taiwan  english taiwan   thailand  english thailand  ไทย turkey  türkçe united kingdom  english united states  english web resources back web resources science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology search amgen worldwide web resources amgen worldwide a biotechnology pioneer since  amgen has reached millions of patients around the world australia english austria deutsch brazil português bulgaria български canada english  français china english   croatia hrvatski czech republic český denmark dansk finland suomen kieli france français germany deutsch greece ελληνικά hong kong   english hungary magyarország ireland english italy italiano japan english   korea english  한국어 mexico español netherlands english  nederlands norway norsk poland język polski portugal português romania limba română russia русский язык singapore english slovakia slovenčina slovenia slovenščina spain español sweden svenska switzerland français  deutsch taiwan english   thailand english  ไทย turkey türkçe united kingdom english united states english web resources amgen has developed a collection of online resources available to help you learn more about areas of interest science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology about overview the amgen difference quick facts mission and values leadership how we operate awards and accolades amgen history science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials manufacturing biosimilars products overview medical information global patient safety counterfeit drug statement safety data sheets responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation access to medicine environment supplier sustainability grants and giving safety and wellness reporting and metrics × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site at amgen our mission is to serve patients we dedicate our days to turning the tide on serious lifeinterrupting illnesses—pushing the boundaries of science to transform medicine fda grants full approval for blincyto® blinatumomab second phase  study improves overall survival with kyprolis® carfilzomib regimen amgen named a  biospace ideal employer learn more about the shape of drugs to come from amgensciencecom recent news more news amgen’s dedication to heart disease amgen is dedicated to the fight against heart disease and has now launched breakaway from heart disease™ the collective goal of this national campaign is to help make america’s heart health a priority learn more searching for the answers within at amgen we believe in a “biology first” approach we use cuttingedge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases amgen believes the cure for disease can be found inside each and every one of us amgen science some of the greatest advances in science are unfolding now inside amgen find out how amgen is elevating research and development to a whole new level learn more pioneer with us if youre seeking a career where you can truly make a difference in the lives of others where you can work at the forefront of biotechnology with the top minds in the field youll find it at amgen view job openings amgen inspires amgen and the amgen foundation inspire the next generation of innovators by funding science education programs at every level from local high schools to the world’s premier educational institutions it’s all part of amgen’s commitment to fuel science innovation and create a brighter healthier future for all learn more biotechnology by amgen find out what it takes to deliver biotechnology medicines to patients learn more amgen pipeline amgen has developed a robust and differentiated pipeline leveraging stateoftheart science to create medicines for serious illnesses learn more amgen inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports amgen inc  product pipeline review   amgen inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports amgen inc  product pipeline review  summaryglobal markets direct’s ‘amgen inc  product pipeline review  ’ provides an overview of the amgen inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of amgen inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of amgen inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of amgen inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the amgen inc’s pipeline productsreasons to buy evaluate amgen inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of amgen inc in its therapy areas of focus identify new drug targets and therapeutic classes in the amgen inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of amgen inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of amgen inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of amgen inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures amgen inc snapshot amgen inc overview key information key facts amgen inc  research and development overview key therapeutic areas amgen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products pipeline products  outlicensed products amgen inc  pipeline products glance amgen inc  late stage pipeline products amgen inc  clinical stage pipeline products amgen inc  early stage pipeline products amgen inc  unknown stage pipeline products amgen inc  drug profiles darbepoetin alfa denosumab panitumumab pegfilgrastim romiplostim adalimumab biosimilar bevacizumab biosimilar bixalomer blinatumomab brodalumab cinacalcet hydrochloride evolocumab ivabradine rilotumumab romosozumab talimogene laherparepvec trastuzumab biosimilar trebananib velcalcetide abrilumab amg amg amg amg amg fulranumab ganitumab omecamtiv mecarbil amg amg amg amg amg amg amg amg amg amg amg amg amg amg amg amg mogamulizumab mt mt solitomab activin type iib receptor antagonist for cancer cachexia am am am amg amg amg amg amg amgen amgen betasecretase  inhibitors for alzheimer disease biaryl amide bite antibody targetting cd bite for solid tumors calcimimetic for secondary hyperparathyroidism cetuximab cetuximab biosimilar dual pik betadelta inhibitors for rheumatoid arthritis and inflammation ep antagonists for alzheimer disease first generation diacylglycerol acyltransferase inhibitor for obesity dyslipidemia and type  diabetes gpr agonists for type  diabetes human beta secretase inhibitor ketobenzimidazoles mcsp bite antibody morpholinone mt multiple myeloma bite phosphoinositide kinase inhibitor for inflammation and oncology recombinant fcfgf rituximab biosimilar second generation diacylglycerol acyltransferase inhibitor for obesity dyslipidemia and type  diabetes small molecule to agonize gpr for undisclosed indication triazine sulfonamide aa cdc kinase inhibitors program drugs for inflammatory bowel disease morpholinone morpholinone small molecule inhibits tankyrase for cancer small molecule targeting gpr amgen inc  pipeline analysis amgen inc  pipeline products by target amgen inc  pipeline products by route of administration amgen inc  pipeline products by molecule type amgen inc  pipeline products by mechanism of action amgen inc  recent pipeline updates amgen inc  dormant projects amgen inc  discontinued pipeline products discontinued pipeline product profiles amgen inc  company statement amgen inc  locations and subsidiaries head office other locations  subsidiaries amgen inc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesamgen inc key information amgen inc key facts amgen inc  pipeline by indication  amgen inc  pipeline by stage of development  amgen inc  monotherapy products in pipeline  amgen inc  partnered products in pipeline  amgen inc  partnered products combination treatment modalities  amgen inc  outlicensed products in pipeline  amgen inc  outlicensed products combination treatment modalities  amgen inc  preregistration  amgen inc  filing rejectedwithdrawn  amgen inc  phase iii  amgen inc  phase ii  amgen inc  phase i  amgen inc  preclinical  amgen inc  discovery  amgen inc  unknown  amgen inc  pipeline by target  amgen inc  pipeline by route of administration  amgen inc  pipeline by molecule type  amgen inc  pipeline products by mechanism of action  amgen inc  recent pipeline updates  amgen inc  dormant developmental projects amgen inc  discontinued pipeline products  amgen inc other locations amgen inc subsidiaries amgen inc key manufacturing facilities list of figuresamgen inc  pipeline by top  indication  amgen inc  pipeline by stage of development  amgen inc  monotherapy products in pipeline  amgen inc  partnered products in pipeline  amgen inc  outlicensed products in pipeline  amgen inc  pipeline by top  target  amgen inc  pipeline by top  route of administration  amgen inc  pipeline by top  molecule type  amgen inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send amgen pipeline  preclinical and clinical targets with strong genetic support the industrys largest toolkit with  modalities a mix of innovative molecules potential new indications and biosimilars a robust and differentiated pipeline leveraging stateoftheart science to create medicines for serious illness amgen is focused on highquality candidates that demonstrate large clinicallyrelevant effects human genetic validation is used whenever possible to enhance the likelihood of success download pipeline chart therapeutic area all modality all search search    modalities in use across pipeline and marketed products modality refers to the structural template of a therapeutic agent †   amgen has an additional three biosimilar programs in development which are undisclosed at this time ‡   tradename provisionally approved by the united states food and drug administration phase one i phase  clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects phase two i phase  clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study phase three i phase  clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study biosimilars † i a biosimilar or followon biologic is a biologic medicine designed to have active properties similar to one that has previously been licensed biosimilars follow a different regulatory review pathway than innovative products and indications amgnnasdaq gs stock quote  amgen inc  bloomberg markets error could not add to watchlist x  watchlist amgen inc amgnus nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  am alphabet slides after a soso quarter   things you must know before the market opens  the street  am to trade earnings you need a mercenary heart market recon  the street  am alphabet slides after a soso quarter   things you must know before the market opens  the street  am alphabet slides after a soso quarter   things you must know before the market opens  the street  am alphabet slides after a soso quarter   things you must know before the market opens  the street  bay state biotech report amgen radius osteoporosis drugs  new cholesterol drug falls short as sales driver for amgen there are currently no news stories for this ticker please check back later  am bioengineered protein drugs market worth us billion by  increasing drugs in phase iii of clinical trials to boost the  fda accepts biologics license application for aimovig™ erenumab  amgen announces webcast of  second quarter financial results  amgen and array biopharma announce preclinical license and collaboration agreement in inflammation  ligand enters into commercial license and supply agreement with amgen for rights to use captisol in the formulation of amg   amgen and ucb provide update on regulatory status of evenity™ romosozumab in the us  amgen submits regulatory applications in us and europe to include overall survival data in kyprolis® carfilzomib label  amgen and allergan to discuss data supporting biologics license application for abp  a biosimilar candidate to avastin® b  second phase  study shows kyprolis® carfilzomib regimen significantly improves overall survival in patients with relapsed m  fda grants full approval for blincyto® blinatumomab to treat relapsed or refractory bcell precursor acute lymphoblastic leu there are currently no press releases for this ticker please check back later profile amgen inc is an independent biotechnology medicines company that discovers develops manufactures and markets medicines for grievous illnesses the company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology address one amgen center drivebuilding thousand oaks ca united states phone  website wwwamgencom executives board members robert a bradway chairmanpresidentceo david w meline exec vpcfo anthony c hooper tony exec vpglobal commercial ops brian m mcnamee exec vpfull potential initiatives esteban santos exec vpoperations show more amgen inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report amgen inc  product pipeline review   published by global markets direct product code  published march   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license amgen inc  product pipeline review   published march   content info  pages description summary global markets directs amgen inc  product pipeline review   provides an overview of the amgen incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by amgen inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of amgen inc the report provides overview of amgen inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses amgen incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features amgen incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate amgen incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for amgen inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding amgen incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures amgen inc snapshot amgen inc overview key information key facts amgen inc  research and development overview key therapeutic areas amgen inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products pipeline products  outlicensed products amgen inc  pipeline products glance amgen inc  late stage pipeline products amgen inc  clinical stage pipeline products amgen inc  early stage pipeline products amgen inc  drug profiles adalimumab biosimilar blinatumomab darbepoetin alfa denosumab etanercept etelcalcetide hydrochloride romiplostim amg bevacizumab biosimilar evolocumab fulranumab panitumumab rituximab biosimilar romosozumab trastuzumab biosimilar trebananib abrilumab amg amg amg amg amg ganitumab omecamtiv mecarbil mr rilotumumab tezepelumab amg talimogene laherparepvec amg amg amg amg amg amg amg amg amg amg amg amg amg amg amg amg amg amgxxx infliximab biosimilar pasotuxizumab solitomab am am am am am am amg amg amg amg amg amg amg amg amg biosimilar  for undisclosed indication biosimilar  for undisclosed indication biosimilar  for undisclosed indication calcimimetic cetuximab biosimilar drug for atherosclerosis drugs to inhibit fgf for bone disorders morpholinone recombinant peptide to block kv ion channel for autoimmune diseases recombinant protein to agonize fgfr for type  diabetes small molecule  to inhibit diacylglycerol acyltransferase for obesity dyslipidemia and type  diabetes small molecule  to inhibit diacylglycerol acyltransferase for obesity dyslipidemia and type  diabetes small molecule to agonize gpr for undisclosed indication small molecule to agonize gpr receptor for undisclosed indication small molecule to agonize gpr for type  diabetes small molecule to antagonize ep receptor for alzheimer disease small molecule to inhibit bace for alzheimers disease small molecule to inhibit pik betadelta for rheumatoid arthritis small molecule to inhibit pikmtor for cancer small molecule to modulate gamma secretase for alzheimers disease small molecules to inhibit bace for alzheimer disease small molecules to inhibit pdea for neurological diseases small molecules to inhibit pik delta for inflammation xmab xmab aa drugs for inflammatory bowel disease monoclonal antibodies for cancer and inflammation morpholinone morpholinone small molecules to inhibit cdc kinase for cancer small molecules to inhibit irak for inflammation small molecules to inhibit nik for multiple myeloma small molecules to inhibit tankyrase for cancer amgen inc  pipeline analysis amgen inc  pipeline products by target amgen inc  pipeline products by route of administration amgen inc  pipeline products by molecule type amgen inc  pipeline products by mechanism of action amgen inc  recent pipeline updates amgen inc  dormant projects amgen inc  discontinued pipeline products discontinued pipeline product profiles amgen inc  company statement amgen inc  locations and subsidiaries head office other locations  subsidiaries amgen inc  key manufacturing facilities appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables amgen inc key information amgen inc key facts amgen inc  pipeline by indication  amgen inc  pipeline by stage of development  amgen inc  monotherapy products in pipeline  amgen inc  partnered products in pipeline  amgen inc  partnered products combination treatment modalities  amgen inc  outlicensed products in pipeline  amgen inc  outlicensed products combination treatment modalities  amgen inc  preregistration  amgen inc  filing rejectedwithdrawn  amgen inc  phase iii  amgen inc  phase ii  amgen inc  phase i  amgen inc  preclinical  amgen inc  discovery  amgen inc  pipeline by target  amgen inc  pipeline by route of administration  amgen inc  pipeline by molecule type  amgen inc  pipeline products by mechanism of action  amgen inc  recent pipeline updates  amgen inc  dormant developmental projects amgen inc  discontinued pipeline products  amgen inc other locations amgen inc subsidiaries amgen inc key manufacturing facilities list of figures amgen inc  pipeline by top  indication  amgen inc  pipeline by stage of development  amgen inc  monotherapy products in pipeline  amgen inc  partnered products in pipeline  amgen inc  outlicensed products in pipeline  amgen inc  pipeline by top  target  amgen inc  pipeline by route of administration  amgen inc  pipeline by molecule type  amgen inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved amgen medinfo  home home medical professionals medical information medical information  amgen login  register home submit an inquiry prescribing info for registered users personal library search for content schedule time with medinfo medical information this application is intended for us healthcare professionals only amgen recommends the use of its products only in accordance with the food and drug administration fdaapproved prescribing information please refer to the full prescribing information for approved product labeling and important safety information please call amgen  to report adverse events or product complaints to contact a medical information healthcare professional directly phone amgen  please review our terms of use and privacy policy before continuing click here to learn about amgen products and view the current prescribing information   amgen inc all rights reserved microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft plus size clothing for women  macys sign in stores book an appointment find a store find an event stores customer service my bag  women womens clothing activewear basic clothing blazers capris coats dresses jackets jeans jumpsuits  rompers leggings lingerie  shapewear maternity pajamas  robes pants shorts skirts suits  suit separates sweaters swimwear tights socks  hosiery tops wear to work plus sizes dresses pants  capris swimwear tops trendy plus size all plus sizes petites cardigans dresses jeans pants  capris tops all petites new  now avec les filles bare shoulder graphic tees  sweatshirts new arrivals soft pant trend shop womens brands adrianna papell alfani calvin klein charter club inc international concepts lauren ralph lauren michael michael kors nike style  co the fur vault the north face tommy hilfiger under armour vince camuto see all brands featured shops cashmere shop dress edit must haves petite fit guide plus must haves  fit guide sports fan shop by lids swim finder the wedding shop contemporary brands bar iii free people levis lucky brand rachel rachel roy all contemporary clothing designer brands eileen fisher polo ralph lauren all designer clothing shoes handbags  more beauty handbags belts hats  scarves jewelry  watches shoes sunglasses tech shop popup sale  off clearance men home bed  bath shoes handbags beauty kids juniors jewelry watches active brands wedding registry gift cards deals  promotions lists dal headerxapi   edt l wed jun   utc   popular searches bathing suits calvin klein calvin klein dresses lauren ralph lauren womens michael kors nike womens tommy hilfiger womens tops  plus size womens dresses womens tops plus size clothinglooking for an amazing selection of plus size clothes for women there are so many styles colors and brands waiting for you to discover shop stylish options for all occasions and find many pieces available in fun vibrant colors such as sizzling confident red warm blush pink and soft feminine purple for casual daytoday outfits find cute and comfortable tops along with figure flattering plus size jeans a pair of slim rocker bootcut blue jeans from seven pairs matches well with a blouse teeshirt sweater or jacket for plus size clothing for women with dramatic contrast and just as much comfort slip into some straight leg black wash jeans from not your daughters jeans and go feminine chick with a long sleeve shawl in luxurious cashmere get great tops for any season from tank tops to sweaters polish your work wardrobe with sharp and sophisticated plus size pant suits and skirt suits mix and match suit separates from anne klein blazers with bottoms of our choice look for slimming pinstripe trousers or office appropriate pencil skirts in extended sizes tahari offers lovely textured jackets and kasper suits features beautiful prints find a wonderful selection of dressy plus size clothes for women start a special evening out by slipping into dazzling formalwear or add some eye catching contrast with a oneshouldered aline dress from international concepts ruby rox carries plus size dresses for attending an evening event or a wedding for more casual occasions and daytoday wear look for dresses that can be worn to work or to a dinner date from suit jackets to halter tops and evening gowns to jeans youll find fashionable plus size clothing for women youre looking for at macyscom shop at macy’s for the latest trends in regular and extended sizes to ensure youre getting the best shopping experience please enable javascript in your browser preferences plus sizes popup sale  off clearance plus size clothing activewear coats dresses graphic tees jackets  blazers jeans jumpsuits  rompers leggings lingerie  shapewear maternity pajamas  robes pants  capris shorts skirts suits  suit separates sweaters swimwear tops trendy plus sizes vests wear to work petite plus size all petite plus size plus size brands alfani alfani anne klein anne klein calvin klein calvin klein charter club charter club city chic city chic inc international concepts inc international concepts lauren ralph lauren lauren ralph lauren michael michael kors michael michael kors style  co style  co tommy hilfiger tommy hilfiger rachel rachel roy curvy collection american rag jessica simpson jm collection karen scott melissa mccarthy seven silver jeans celebrity pink plus jones new york levis lucky brand jeans tahari asl ideology material girl slink jeans mblm by tess holliday see all brands featured shops macyslove photo gallery back to school denim destination dress edit how to wear it must haves  fit guide the wedding shop shoes  accessories handbags  accessories hats scarves  wraps hosiery shoes sunglasses plus size sale  clearance    shop our ultimate popup sale  off select tops  off select shorts  capris  off select dresses  off trendy plus  designer tops dresses pants  capris cardigans swim shorts jeans jackets  blazers   overview read all reviews or call   buy macy   see full product details qty  plus sizes quickview     mcom footerxapi   edt l wed jun   utc   dal catalog  catsplash page layout  canvas navappreplicam mamlvnav   edt l sat jul   utc   goyou  macys health  fitness guide – macys macysis yourcenterfor eatingliving being wellin the stcenturygoyoustrengthen your formnourish your bodyrestore your soulchoose what makes you sweattrainingwomenmenrunningwomenmenoutdoorswomenmengolfwomenmenfinish lineout and about in the latestwomenmenkidsbrands we lovenourishwe all know health is an inside job its time to hit the kitchenshop the essentialstop  nourish picks   featured categoriesjuicersblenderswater bottlesculinary councilcookware  electricskitchen gadgetsbrands we lovetips for a healthiernew yearwhether you resolved to lose weight or simply want to fuel up for a busy day check out these tips from the macys culinary councilcheck it outrestorerr speeds up recovery heres how to treat yourself bettershop the essentialstop  restore picks featured categoriessunscreens  lotionsmattressessleep solutionsair purifierspersonal caresport sunglassesbrands we love× your browser does not support the video tag amgen amgn  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in amgen inc amgn  last  days median target price   upside positive ratings  of  analysts latest  cowen  outperform     view all analyst ratings for amgn » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising amgen about back about overview the amgen difference quick facts mission and values leadership how we operate back how we operate overviewcorporate governancebusiness ethics and compliancepolicies practices and disclosures awards and accolades back awards and accolades overview amgen history science back science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials back clinical trials overviewabout clinical trialsamgen clinical trialsinformation for healthcare professionalsclinical trial transparency data sharing and disclosure practicesclinical outofhours support programinvestigator sponsored studies manufacturing biosimilars products back products overview medical information global patient safety back global patient safety overviewadverse event and product complaint reporting counterfeit drug statement safety data sheets responsibility back responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation back amgen foundation overviewprograms for students programs for teachers about the amgen foundation staff engagement access to medicine back access to medicine overviewreimbursement support services and financial assistance programsaccess to investigational medicinesthe value of our medicines environment supplier sustainability grants and giving back grants and giving overviewamgen foundation grantsindependent medical education fundingus healthcare donationsnonhealthcare donations and sponsorshipsequipment donationsdonation and grant recipient list safety and wellness back safety and wellness overviewsafetywellness reporting and metrics contact us back contact us locations product inquiries investors media partners careers amgen worldwide back amgen worldwide australia  english austria  deutsch brazil  português bulgaria  български canada  english canada  français china  english china   croatia  hrvatski czech republic  český denmark  dansk finland  suomen kieli france  français germany  deutsch greece  ελληνικά hong kong   hong kong  english hungary  magyarország ireland  english italy  italiano japan  english japan   korea  english korea  한국어 mexico  español netherlands  english netherlands  nederlands norway  norsk poland  język polski portugal  português romania  limba română russia  русский язык singapore  english slovakia  slovenčina slovenia  slovenščina spain  español sweden  svenska switzerland  français switzerland  deutsch taiwan  english taiwan   thailand  english thailand  ไทย turkey  türkçe united kingdom  english united states  english web resources back web resources science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology search amgen worldwide web resources amgen worldwide a biotechnology pioneer since  amgen has reached millions of patients around the world australia english austria deutsch brazil português bulgaria български canada english  français china english   croatia hrvatski czech republic český denmark dansk finland suomen kieli france français germany deutsch greece ελληνικά hong kong   english hungary magyarország ireland english italy italiano japan english   korea english  한국어 mexico español netherlands english  nederlands norway norsk poland język polski portugal português romania limba română russia русский язык singapore english slovakia slovenčina slovenia slovenščina spain español sweden svenska switzerland français  deutsch taiwan english   thailand english  ไทย turkey türkçe united kingdom english united states english web resources amgen has developed a collection of online resources available to help you learn more about areas of interest science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology about overview the amgen difference quick facts mission and values leadership how we operate awards and accolades amgen history science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials manufacturing biosimilars products overview medical information global patient safety counterfeit drug statement safety data sheets responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation access to medicine environment supplier sustainability grants and giving safety and wellness reporting and metrics × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site at amgen our mission is to serve patients we dedicate our days to turning the tide on serious lifeinterrupting illnesses—pushing the boundaries of science to transform medicine fda grants full approval for blincyto® blinatumomab second phase  study improves overall survival with kyprolis® carfilzomib regimen amgen named a  biospace ideal employer learn more about the shape of drugs to come from amgensciencecom recent news more news amgen’s dedication to heart disease amgen is dedicated to the fight against heart disease and has now launched breakaway from heart disease™ the collective goal of this national campaign is to help make america’s heart health a priority learn more searching for the answers within at amgen we believe in a “biology first” approach we use cuttingedge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases amgen believes the cure for disease can be found inside each and every one of us amgen science some of the greatest advances in science are unfolding now inside amgen find out how amgen is elevating research and development to a whole new level learn more pioneer with us if youre seeking a career where you can truly make a difference in the lives of others where you can work at the forefront of biotechnology with the top minds in the field youll find it at amgen view job openings amgen inspires amgen and the amgen foundation inspire the next generation of innovators by funding science education programs at every level from local high schools to the world’s premier educational institutions it’s all part of amgen’s commitment to fuel science innovation and create a brighter healthier future for all learn more biotechnology by amgen find out what it takes to deliver biotechnology medicines to patients learn more amgen pipeline amgen has developed a robust and differentiated pipeline leveraging stateoftheart science to create medicines for serious illnesses learn more amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info amgen about back about overview the amgen difference quick facts mission and values leadership how we operate back how we operate overviewcorporate governancebusiness ethics and compliancepolicies practices and disclosures awards and accolades back awards and accolades overview amgen history science back science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials back clinical trials overviewabout clinical trialsamgen clinical trialsinformation for healthcare professionalsclinical trial transparency data sharing and disclosure practicesclinical outofhours support programinvestigator sponsored studies manufacturing biosimilars products back products overview medical information global patient safety back global patient safety overviewadverse event and product complaint reporting counterfeit drug statement safety data sheets responsibility back responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation back amgen foundation overviewprograms for students programs for teachers about the amgen foundation staff engagement access to medicine back access to medicine overviewreimbursement support services and financial assistance programsaccess to investigational medicinesthe value of our medicines environment supplier sustainability grants and giving back grants and giving overviewamgen foundation grantsindependent medical education fundingus healthcare donationsnonhealthcare donations and sponsorshipsequipment donationsdonation and grant recipient list safety and wellness back safety and wellness overviewsafetywellness reporting and metrics contact us back contact us locations product inquiries investors media partners careers amgen worldwide back amgen worldwide australia  english austria  deutsch brazil  português bulgaria  български canada  english canada  français china  english china   croatia  hrvatski czech republic  český denmark  dansk finland  suomen kieli france  français germany  deutsch greece  ελληνικά hong kong   hong kong  english hungary  magyarország ireland  english italy  italiano japan  english japan   korea  english korea  한국어 mexico  español netherlands  english netherlands  nederlands norway  norsk poland  język polski portugal  português romania  limba română russia  русский язык singapore  english slovakia  slovenčina slovenia  slovenščina spain  español sweden  svenska switzerland  français switzerland  deutsch taiwan  english taiwan   thailand  english thailand  ไทย turkey  türkçe united kingdom  english united states  english web resources back web resources science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology search amgen worldwide web resources amgen worldwide a biotechnology pioneer since  amgen has reached millions of patients around the world australia english austria deutsch brazil português bulgaria български canada english  français china english   croatia hrvatski czech republic český denmark dansk finland suomen kieli france français germany deutsch greece ελληνικά hong kong   english hungary magyarország ireland english italy italiano japan english   korea english  한국어 mexico español netherlands english  nederlands norway norsk poland język polski portugal português romania limba română russia русский язык singapore english slovakia slovenčina slovenia slovenščina spain español sweden svenska switzerland français  deutsch taiwan english   thailand english  ไทย turkey türkçe united kingdom english united states english web resources amgen has developed a collection of online resources available to help you learn more about areas of interest science resources amgen pipeline amgen science biotechnology by amgen introduction to biotechnology disease education breakaway from heart disease™ breakaway from cancer® preventing infections in cancer patients blood counts areas of focus amgen biosimilars amgen business development amgen foundation amgen oncology about overview the amgen difference quick facts mission and values leadership how we operate awards and accolades amgen history science overview research and development strategy pipeline scientific advisory boards amgen science clinical trials manufacturing biosimilars products overview medical information global patient safety counterfeit drug statement safety data sheets responsibility overview amgen’s commitment to patients  responsibility highlights report amgen foundation access to medicine environment supplier sustainability grants and giving safety and wellness reporting and metrics × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site × do you want to link to this external site and leave amgencom no return to amgencom  yes leave amgencom you are now leaving amgens web site amgen takes no responsibility for and exercises no control over the organizations views or accuracy of the information contained on this server or site at amgen our mission is to serve patients we dedicate our days to turning the tide on serious lifeinterrupting illnesses—pushing the boundaries of science to transform medicine fda grants full approval for blincyto® blinatumomab second phase  study improves overall survival with kyprolis® carfilzomib regimen amgen named a  biospace ideal employer learn more about the shape of drugs to come from amgensciencecom recent news more news amgen’s dedication to heart disease amgen is dedicated to the fight against heart disease and has now launched breakaway from heart disease™ the collective goal of this national campaign is to help make america’s heart health a priority learn more searching for the answers within at amgen we believe in a “biology first” approach we use cuttingedge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases amgen believes the cure for disease can be found inside each and every one of us amgen science some of the greatest advances in science are unfolding now inside amgen find out how amgen is elevating research and development to a whole new level learn more pioneer with us if youre seeking a career where you can truly make a difference in the lives of others where you can work at the forefront of biotechnology with the top minds in the field youll find it at amgen view job openings amgen inspires amgen and the amgen foundation inspire the next generation of innovators by funding science education programs at every level from local high schools to the world’s premier educational institutions it’s all part of amgen’s commitment to fuel science innovation and create a brighter healthier future for all learn more biotechnology by amgen find out what it takes to deliver biotechnology medicines to patients learn more amgen pipeline amgen has developed a robust and differentiated pipeline leveraging stateoftheart science to create medicines for serious illnesses learn more amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view amgen amgen  twitter skip to content home home home current page moments moments moments current page search query search twitter searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어  简体 繁體 have an account log in have an account remember me · forgot password new to twitter sign up amgenverified account amgen tweets tweets current page  following following  followers followers k likes likes    more likes unmute amgen mute amgen follow following unfollow blocked unblock pending cancel amgenverified account amgen committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering developing  manufacturing innovative therapeutics thousand oaks ca usa amgencom joined april   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked amgen are you sure you want to view these tweets viewing tweets wont unblock amgen yes view profile close amgen followed amgen retweeted amgen biosimilars‏ amgenbiosim jul  more copy link to tweet embed tweet embed video didyouknow biosimilar medicines are made from natural sources like yeast bacteria human and animal cells httpbitlymuncd pictwittercomfxcnynjbm  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen h hours ago more copy link to tweet embed tweet see how we’ve been manufacturing biotech excellence for more than three decades httpbitlypop pictwittercombdlcrrjlq  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen h hours ago more copy link to tweet embed tweet embed video dr david siegel and his daughter talk about life as a myeloma physician bloodcounts amgenoncopictwittercomtupaocqixk  reply  retweets  likes reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo amgen retweeted amgen foundation‏ amgenfoundation jul  more copy link to tweet embed tweet dyk that students participating in the biotechexperience at venturacollege extracted dna  spliced geneshttpbitlytavbew   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen retweeted amgen biosimilars‏ amgenbiosim jul  more copy link to tweet embed tweet our mission is to transform the power of biotechnology into therapies that restore health and save liveshttpscardstwittercomcardsceywfexbn …  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet amid the and summer fun remember to stay hearthealthy americanheart shares tips for protecting your in july httpbitlysxlhy   reply  retweets  likes reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet we’re fighting disease w groundbreaking modalities discover the beating heart of drug innovation in amgen’s labshttpscardstwittercomcardscevhwjyja …  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet migraine can affect peoples’ lives even when they are not experiencing an attack rt to show your support  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen retweeted amgen biosimilars‏ amgenbiosim jul  more copy link to tweet embed tweet the fda bases biosimilar approval on robust analytical nonclinical and clinical data learn morehttpscardstwittercomcardsceywfexbns …  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet neutropenia is the most serious hematologic toxicity during treatment with chemo learn more from cdcfound httpbitlyoddt   reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet amgen has reduced carbon emissions by  percent since  see our  responsibility highlights report httpbitlyrajzj pictwittercomtphhvp  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet early biotech scientists found a great source of cell cultures in the ovary of what animal learn more httpbitlypdbi pictwittercomyzarfyeti  reply  retweets  likes reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet pregnancy registries help track effects certain medicines have on the health of a mother  her baby learn more httpsmothertobabyorgongoingstudies …  reply  retweet  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen retweeted amgen biosimilars‏ amgenbiosim jul  more copy link to tweet embed tweet cqas are vital to ensuring that biosimilar medicines work as intended learn morehttpscardstwittercomcardsceywfexbni …  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen retweeted amgen foundation‏ amgenfoundation jul  more copy link to tweet embed tweet we love to see amgen staff giving back including rob from idaho he recently volunteered at a local soup kitchen amgenimpactpictwittercomltvbeyafbv  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet usfda accepts amgen bla submission for aimovig™ erenumab httpbitlyugyzgk   replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet amgen announces webcast of  second quarter financial results httpbitlyvftnj  amgn  replies  retweets  likes reply  retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet cart oncolytic immunotherapy viruses  bites redefined clinical medicine now amgen has two new contendershttpscardstwittercomcardscevhwjykf …  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet were dedicated to helping patients caregivers  families impacted by migraine continue the dialogue with us httpbitlysdxpy   reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen‏verified account amgen jul  more copy link to tweet embed tweet meet paul nioi a scientist in the research  development group khanacademy shares morehttpbitlytkyyex   replies  retweet  like reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo amgen hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile searches you follow follow following unfollow saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user amgen  wikipedia amgen from wikipedia the free encyclopedia jump to navigation search amgen inc amgen headquarters in thousand oaks california formerly called applied molecular genetics – type public traded as nasdaq amgn nasdaq component sp  component sp  component sehk  industry biotechnology founded  headquarters thousand oaks california us key people robert a bradway chairman president and ceo products epogen aranesp kineret enbrel neulasta neupogen nplate vectibix prolia xgeva and sensiparmimpara revenue us billion  operating income us billion   net income us billion  total assets us billion  total equity us billion  number of employees  december  website wwwamgencom amgen inc formerly applied molecular genetics inc is an american multinational biopharmaceutical company headquartered in thousand oaks california located in the conejo valley amgen is the worlds largest independent biotechnology firm in  the companys largest selling product lines were neulastaneupogen two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy and enbrel a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases other products include epogen aranesp sensiparmimpara nplate vectibix prolia and xgeva contents  history  timeline  acquisition timeline  acquisition history  products  products developed and then sold off  pipeline  clinical trials  see also  references  external links historyedit amgen corporate logo  amgens corporate gulfstream v departs fox field lancaster california the word amgen is a portmanteau of the companys original name applied molecular genetics which became the official name of the company in  three years after incorporation and coincident with its initial public offering the companys first chief executive officer from  was cofounder george b rathmann followed by gordon m binder in  followed by kevin w sharer in  robert a bradway became amgen’s president and chief executive officer in may  following sharers retirement the company has made at least five major corporate acquisitions timelineedit  william bowes from cetus corporation recruits winston salser from ucla to start amgen with a scientific advisory board consisting of normam davidson leroy hood arnold berk john carbon robert schimke arno motulsky marvin h caruthers and dave gibson  amgen received approval for the first recombinant human erythropoetin product epogen for the treatment of anemia associated with chronic kidney failure epogen also marketed by johnson and johnson under the tradename procrit would later be approved for anemia due to cancer chemotherapy anemia due to treatment with certain hiv drugs and for the reduction of the need for transfusions associated with surgery  in february  amgen received fda approval for neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy a  metaanalysis found that neupogen treatment reduced the risk of febrile neutropenia by  reduced the risk of documented infection by  and reduced the risk of infectionrelated mortality by   in november  immunex a future acquisition of amgen received approval for enbrel etanercept the first rheumatoid arthritis drug targeting tumor necrosis factor alpha tnfalpha a  assessment by the national institute of clinical excellence of the united kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors are effective treatments compared with placebo for ra patients who are not well controlled by conventional dmards improving control of symptoms improving physical function and slowing radiographic changes in joints a more recent study demonstrated that compared to traditional diseasemodifying antirheumatic drugs treatment with etanercept improved survival reduced cardiovascular events and reduced the incidence of hematological cancers  on june   amgen received fda approval for prolia a protein drug for the treatment of postmenopausal osteoporosis in clinical trials prolia reduced the rate of vertebral fractures by  and the risk of hip fractures by   in november  the fda approved xgeva for the prevention of complications of bone metastases in patients with solid tumors the clinical trials primarily enrolled patients with breast or prostate cancer  illegal marketing practices the los angeles times reported on december   that amgen pleaded guilty and agreed to pay  million in criminal penalty and  million to resolve  related whistleblower complaints federal prosecutors accused the company of pursuing profits while putting patients at risk larry husten a contributor at forbescom elaborates on amgens illegal marketing practices in this case namely that the government accused amgen of marketing aranesp for indications not approved by the fda and other illegal marketing practices one of the drugs mentioned in the lawsuit had sales of  million in the third quarter of  down  from the same quarter the previous year due to reimbursement problems and label changes  amgen paid  million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs  lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes sensipar without government controls for an additional two years the new york times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated  million but other assessments concluded that the change would protect seniors in rural areas and reduce overall medicare spending  in september the company announced it would acquire dezima pharma for more than  billion the same day the company announced a collaboration with xencor on  early stage immunooncology and inflammation programmes as part of the deal amgen will pay  million upfront with the deal being worth up to another  billion  in september the company announced it would purchase the rights to boehringer ingelheims phase i bispecific tcell engager compound bi  now amg  for use in the treatment of multiple myeloma acquisition timelineedit  – synergen inc  – kinetix pharmaceuticals inc  – immunex corporation  – tularik inc  – abgenix inc  – avidia inc  – alantos pharmaceuticals  – ilypsa inc  – alantos pharmaceuticals holdings inc  – biovex group inc  – laboratório químico farmacêutico bergamo ltda  – micromet inc  – mustafa nevzat i̇laç  – kai pharmaceuticals  – decode genetics  – onyx pharmaceuticals inc  – dezima pharma  – catherex acquisition historyedit the following is an illustration of the companys mergers acquisitions spinoffs and historical predecessors amgen amgen founded  as applied molecular genetics synergen inc acq  kinetix pharmaceuticals inc acq  immunex corporation acq  tularik inc acq  abgenix inc acq  avidia inc acq  alantos pharmaceuticals acq  ilypsa inc acq  alantos pharmaceuticals holdings inc acq  biovex group inc acq  laboratório químico farmacêutico bergamo ltda acq  micromet inc acq  mustafa nevzat i̇laç acq  kai pharmaceuticals acq  decode genetics acq  onyx pharmaceuticals acq  nextcode genetics spun off  dezima pharma acq  catherex acq  productsedit as of december  amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions conditions lists are highly generalized see each article for more detail aranesp darbepoetin alfa for anemia blincyto blinatumomab for the treatment of acute lymphoblastic leukemia enbrel etanercept for various forms of arthritis epogen epoetin also known as procrit for anemia neulasta peg granulocytecolony stimulating factor or pegfilgrastim for neutropenia neupogen granulocytecolony stimulating factor for neutropenia nplate romiplostim for chronic immune thrombocytopenic purpura prolia denosumab for postmenopausal osteoporosis sensiparmimpara cinacalcet for primary  secondary hyperparathyroidism a mineral metabolism complication common in patients with kidney failure vectibix panitumumab for colon cancer xgeva denosumab for the prevention of skeletalrelated events sres pathological fracture radiation to bone spinal cord compression or surgery to bone in adults with bone metastases from solid tumors kyprolis repatha parsabiv products developed and then sold offedit kepivance palifermin for oral mucositis sold to biovitrium now swedish orphan biovitrum in december  stemgen ancestim for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells sold to biovitrium now swedish orphan biovitrum in december  kineret anakinra for rheumatoid arthritis exclusively licensed to biovitrium now swedish orphan biovitrum in december  pipeline  clinical trialsedit as of december  amgen had  drugs in phase iii clinical trials in november  the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy than those without later in the same week the company in conjunction with astrazeneca reported positive results for brodalumab in a phase iii trial comparing the compound with ustekinumab and a placebo in treating psoriasis in march  the company announced it would license its phase ii candidate drug amg  to developer celimmune who plan to develop the antiil monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease in june  amgen presented phase  clinical trial data for their anticgrp antibody amg  for migraine see alsoedit california portal companies portal kirinamgen v hoechst marion roussel a uk patent case decided by the house of lords amgen inc v harris a united states supreme court case on employment law evolocumab referencesedit  a b amgen  sec filings k amgencom retrieved  july    amgen history official site page accessed january    ronald vogel pharmaceutical economics and public policy crc press  isbn  p   amgen form k annual report filing date mar   secdatabasecom retrieved jan     amgen form k filing date mar   secdatabasecom retrieved jan     amgen form k current report filing date may   secdatabasecom retrieved jan     amgen—a biotechnology success story  from drug development to the mass market   a b drugsfda fda approved drug products   drugsfda fda approved drug products   lyman gh kuderer nm djulbegovic b april  prophylactic granulocyte colonystimulating factor in patients receiving doseintensive cancer chemotherapy a metaanalysis am j med   – pmid  dois   chen yf jobanputra p barton p et al november  a systematic review of the effectiveness of adalimumab etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their costeffectiveness health technol assess   iii–iv xi–xiii – pmid  doihta   morgan cl emery p porter d et al january  treatment of rheumatoid arthritis with etanercept with reference to diseasemodifying antirheumatic drugs longterm safety and survival using prospective observational data rheumatology oxford   – pmid  doirheumatologyket   drugsfda fda approved drug products   wwwaccessdatafdagov pdf   fda approves xgeva to help prevent cancerrelated bone injury   terhune chad  december  amgen pleads guilty to improper marketing of anemia drug aranesp los angeles times retrieved  february    husten larry amgen pleads guilty to misbranding anemia drug aranesp forbes retrieved  february    article  amgens aranesp fails in heart trial singapore plant planned   amgen inc pleads guilty to federal charge in brooklyn and pays  million to resolve criminal liability and civil fraud allegations press release department of justice – office of public affairs december   retrieved  october    lipton eric  january  fiscal footnote big senate gift to drug maker new york times retrieved  february    jon entine new york times mum after congressional budget office rebukes bungled amgenmedicare investigation huffington post  february    cbo analysis shows keeping oral drugs out of esrd bundle could save money  nephrology news  issues archived from the original on    a b for up to b amgen acquires dezima pharma gen   amgen bets up to b on xencors antibody technology fiercebiotech   amgen xencor to partner on cancer immunotherapy inflammation drugs gen   amgen buys rights to myeloma bite immunotherapy from boehringer ingelheim  gen news highlights  gen   amgen form ka filing date feb   secdatabasecom retrieved jan     amgen form  filing date oct   secdatabasecom retrieved jan     amgen form k current report filing date dec   secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date mar   pdf secdatabasecom retrieved jan     amgen form k current report filing date dec   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     amgen  media  news release amgencom   amgen form k current report filing date sep   secdatabasecom retrieved jan     amgen  media  news release amgencom   a b amgen form q quarterly report filing date aug   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   secdatabasecom retrieved jan     amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     amgen form k current report filing date jan   pdf secdatabasecom retrieved jan     amgen form k current report filing date apr   pdf secdatabasecom retrieved jan     türk ilaç devi  milyon dolara satýldý hurriyetcomtr   amgen form q quarterly report filing date may   pdf secdatabasecom retrieved jan     guha malini october   amgen swallows onyx whole nature biotechnology  – pmid  doinbt retrieved november     amgen acquires catherex spinoff from medigene  gen news highlights  gen   food and drug administration december   fda press release blinatumomab  a b c amgen press office biovitrum closes product acquisition deal with amgen archived july   at the wayback machine  stemgen® ancestim sobicom   amgen phase iii pipeline accessed december    gen  news highlightsamgen halts rilotumumab trials in advanced gastric cancer gen   gen  news highlightsbrodalumabs no turkey in phase iii amgen and astrazeneca gen   gen  news highlightscelimmune licenses amgens amg  for celiac disease gen   httpwwwmedscapecomviewarticle external linksedit official website business data for amgen google finance yahoo finance reuters sec filings amgen sec filings amgen inc company profile at google finance amgn on stockrow v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies v t e companies of the nasdaq index st century fox activision blizzard adobe systems akamai technologies alexion pharmaceuticals alphabet amazoncom american airlines group amgen analog devices apple applied materials autodesk automatic data processing baidu biogen biomarin pharmaceutical broadcom limited ca technologies celgene cerner charter communications check point cintas cisco systems citrix systems cognizant comcast costco csx ctripcom international dentsply sirona discovery communications dish network dollar tree ebay electronic arts expedia express scripts facebook fastenal fiserv gilead sciences hasbro henry schein hologic idexx laboratories illumina incyte intel intuit intuitive surgical j b hunt transport services jdcom klatencor kraft heinz lam research liberty global liberty interactive marriott international mattel maxim integrated products mercadolibre microchip technology micron technology microsoft mondelez international monster beverage mylan netease netflix norwegian cruise line nvidia oreilly auto parts paccar paychex paypal qualcomm regeneron ross stores seagate technology shire sirius xm holdings skyworks solutions starbucks symantec tmobile us tesla inc texas instruments the priceline group tractor supply company ulta beauty verisk analytics vertex pharmaceuticals viacom vodafone walgreens boots alliance western digital wynn resorts xilinx retrieved from httpsenwikipediaorgwindexphptitleamgenoldid categories companies in the nasdaq indexcompanies listed on nasdaqamgenbiotechnology companies of the united statescompanies based in thousand oaks californiacompanies in the nasdaq biotechnology indexlife sciences industrymultinational companies headquartered in the united statesorphan drug companiespharmaceutical companies established in pharmaceutical companies of the united stateshidden categories webarchive template wayback linkspages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages العربيةdanskdeutschespañolفارسیfrançaisbahasa indonesiaitalianonederlandspolskiportuguêsromânăрусскийsuomiукраїнськаtiếng việt edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel